The Irbesartan in Type 2 Diabetes With Microalbuminuria 2 (IRMA-2) and the Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) trials were placebo-controlled studies enrolling patients with moderately increased albuminuria (30–300 mg/g creatinine) [190,191] designed to find whether RASi reduced the risk of development of severely increased albuminuria (>300 mg/g creatinine). This evidence concerns the gene AGT and type 2 diabetes mellitus.